Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 30% UP IN THE NEXT 72 HOURS -- Ignore unavailable to you. Want to Upgrade?

To: rharris who wrote (667)	2/25/1998 10:27:00 AM
From: Brad	Respond to of 1121

ADOT Moving UP on Today's News! - Here's the Story that just came out this morning: biz.yahoo.com -------------------------------------------------- Early Cancer Detection Patents to Benefit Advanced Optics Electronics Inc. ALBUQUERQUE, N.M.--(BW HealthWire)--Feb. 25, 1998--Advanced Optics Electronics Inc. (OTC BB:ADOT - news) today issued a significant report from its Research and Development Division. The Advanced Optics Electronics Inc. Research and Development team announced that BIOMODA Inc. (a medical testing and diagnostics company in which Advanced Optics has a substantial minority interest) is in final negotiations with a significant distinguished cytopathology lab. As mentioned previously, BIOMODA Inc. has an exclusive license to a patented technology for the very early detection of lung cancer. The above lab is slated to become a marketing showcase to demonstrate the efficiency of BIOMODA's low-cost/high-profit tests for sputum samples and pap smears. Primary customers for the cytopathology (the study of disease at the cellular level) reagents (substances used because of their chemical or biological activity) will be medium to large size pathology labs. Additionally, BIOMODA's tests will be used for ''in vivo'' (in the living body) diagnostics and therapeutics. Clinical administration of these tests will be conducted by for-profit cancer treatment centers and National Institutes of Health designated Comprehensive Cancer Centers. Based upon the proprietary nature of BIOMODA's technology and the immense interest in its ability to detect cancer at very early stages (at least six years earlier than currently available tests), BIOMODA has conservatively estimated revenues of $9 million or more in just the third year of commercial administration. A company representative, speaking on the enormous potential of BIOMODA's testing program, said, ''Given Advanced Optics' notable minority interest position in BIOMODA Inc., Advanced Optics is positioned to share in the profits from the nationwide (and later worldwide) introduction of this high-profit testing program.'' This press release contains forward-looking statements with respect to the results of operations and business of the Company that involves risk and uncertainties. Risks and uncertainties of the Company will be detailed from time to time in the Company's periodic reports to be filed with the Securities and Exchange Commission. Contact Advanced Optics Electronics Inc. at 505/797-7878 or for further information visit their web site at www.adot.org. Contact: Advanced Optics Electronics Inc., Albuquerque 505/797-7878 -------------------------------------- Brad